3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
5
Diarrhea
3
Vulvar Neoplasms
1
Vulvar Diseases
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Urogenital Neoplasms
1
Triple Negative Breast Neoplasms
1
Sarcoma, Alveolar Soft Part
1
Recurrence
1
Rectal Neoplasms
1
Papillomavirus Infections
1
Ovarian Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Low Anterior Resection Syndrome
1
Gliosarcoma
1
Glioblastoma
1
Exanthema
1
Colitis
1
Carcinoma in Situ
1
Interventions
pembrolizumab
96
Carboplatin
67
Paclitaxel
56
Cyclophosphamide
40
Capecitabine
30
Specimen Handling
28
sacituzumab govitecan
25
130-nm albumin-bound paclitaxel
24
Gemcitabine
22
Magnetic Resonance Spectroscopy
21
Doxorubicin
20
olaparib
19
Taxes
19
Biopsy
19
Albumin-Bound Paclitaxel
19
Drug Therapy
16
atezolizumab
13
Nivolumab
13
toripalimab
12
Radiotherapy
12
Epirubicin
12
durvalumab
11
Docetaxel
10
Cisplatin
10
Bevacizumab
10
eribulin
9
fludarabine
8
Standard of Care
7
Radiation
7
Injections
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
Loperamide
×
1 year
×
Clear all
NCT05520723
2025-12-04
PRIMED
MedSIR
Phase 2
Completed
50 enrolled